摘要
目的探究帕罗西汀联合氯丙嗪共同治疗精神分裂症的治疗效果与安全性情况。方法挑选100例2018年1月至2020年1月在我院精神科进行治疗的精神分裂症患者随机分为数量相同的对照组和研究组,共两组,研究组选用抗精神病药联合帕罗西汀治疗,对照组选用抗精神病进行治疗。对两组患者治疗前及治疗2周、4周、8周、12周的疗效及不良反应发生率进行比较。结果治疗8周和12周过后,研究组疗效和阴性症状得分显著好于对照组(P<0.01),研究组的总有效率普遍高于对照组(P<0.05),研究组和对照组不良反应发病率差别无统计学意义(P>0.05)。结论帕罗西汀协同氯丙嗪治疗精神分裂症状疗效好,安全系数高。
Objective To analyze the therapeutic effect and safety of paroxetine combined with promethazine in the treatment of schizophrenia..Methods 100 schizophrenic patients were treated to our hospital's psychiatric department from January 2018 to January 2020 were divided into two groups,namely observation group and control group.The observation group was treated with antipsychotics combined with paroxetine,and the control group The group was treated with antipsychotic treatment.The treatment effects and the adverse reactions of the two groups of patients before and 2,4 and 8 weeks after treatment,,and 12 weeks were compared.Results The treatment effect and negative symptom scores after 8 and 12 weeks of treatment,the observation group was significantly better than the control group(P<0.01).Through comparison,it can be found that the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).There was no statistical difference in the incidence of side effects between the observation group and the control group(P>0.05).Conclusion The clinical effect of paroxetine combined with chlorpromazine in the treatment of patients with schizophrenia is relatively obvious and safe.
作者
张卓
ZHANG Zhuo(Kangning Hospital of Liaoning Provincial Demobilized Soldiers,Xingcheng 125100,China)
出处
《中国医药指南》
2022年第29期100-102,共3页
Guide of China Medicine
